SpringerLink
Log in

Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

The p53 tumor suppressor and its negative regulator, murine double minute 2 (MDM2), play critical roles in carcinogenesis. P53 codon 72 and MDM2 309T>G polymorphisms could influence p53 and MDM2 function, respectively, and might affect cancer susceptibility. We therefore investigated the association between these two SNPs, alone or in combination, and the risk of hepatocellular carcinoma (HCC) in Chinese. In this case–control study, we genotyped p53 codon 72 and MDM2 309T>G polymorphisms in 985 HCC cases and 992 cancer-free age- and sex-matched controls and evaluated their associations with the risk of HCC. Although no significant main effects were found for these two SNPs in the single-locus analysis and stratified analysis by age, sex, smoking, drinking, and hepatitis B virus (HBV) infection, we found that individuals carrying at least one G allele of the MDM2 309T>G polymorphism had statistically significant increased risk of HCC among those with the p53 Pro/Pro genotype (adjusted odds ratio (OR) = 2.23, 95 % confidence interval (95%CI) = 1.20–4.14 for TG genotype; adjusted OR = 2.67, 95%CI = 1.32–5.42 for GG genotype), and the interaction between p53 codon 72 and MDM2 309T>G was significant (P interaction = 0.017). Our findings suggest that the interaction of p53 codon 72 and MDM2 309T>G may play an important role in the etiology of HCC. More studies with well-designed and large sample sizes are required to validate these observations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Li Q, Du J, Guan P, Qu CF, Dai M. Estimation and prediction of incidence, mortality and prevalence on liver cancer, in 2008, China. Zhonghua Liu **ng Bing Xue Za Zhi. 2012;33(6):554–7.

    PubMed  Google Scholar 

  3. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S72–8.

    Article  CAS  PubMed  Google Scholar 

  4. Fan Y, Hu D, Feng B, Wang W. The NQO1 C609T polymorphism and hepatocellular carcinoma risk. Tumour Biol. 2014;35(8):7343–50.

    Article  CAS  PubMed  Google Scholar 

  5. Wang C, Zhao H, Zhao X, Wan J, Wang D, Bi W, et al. Association between an insertion/deletion polymorphism within 3′UTR of SGSM3 and risk of hepatocellular carcinoma. Tumour Biol. 2014;35(1):295–301.

    Article  CAS  PubMed  Google Scholar 

  6. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6.

    Article  CAS  PubMed  Google Scholar 

  7. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323–31.

    Article  CAS  PubMed  Google Scholar 

  8. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, Tse CK, Lark AA, Livasy CA, et al. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009;125(7):1735–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, et al. Mutations of the p53 gene in lymphoid leukemia. Blood. 1991;77(6):1153–6.

    CAS  PubMed  Google Scholar 

  10. Dumont P, Leu JI, Della Pietra AC, George 3rd DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.

    Article  CAS  PubMed  Google Scholar 

  11. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ezzikouri S, El Feydi AE, Chafik A, Benazzouz M, El Kihal L, Afifi R, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res. 2007;37(9):748–54.

    Article  CAS  PubMed  Google Scholar 

  13. Sumbul AT, Akkiz H, Bayram S, Bekar A, Akgollu E, Sandikci M. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study. Mol Biol Rep. 2012;39(2):1639–47.

    Article  CAS  PubMed  Google Scholar 

  14. Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol. 2005;11(2):289–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mohana Devi S, Balachandar V, Arun M, Suresh Kumar S, Balamurali Krishnan B, Sasikala K. Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population. Dig Dis Sci. 2013;58(3):759–67.

    Article  CAS  PubMed  Google Scholar 

  16. Yang Y, **a T, Li N, Zhang J, Yang Y, Cong W, et al. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma. Protein Cell. 2013;4(1):71–81.

    Article  CAS  PubMed  Google Scholar 

  17. Yoon YJ, Chang HY, Ahn SH, Kim JK, Park YK, Kang DR, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29(6):1192–6.

    Article  CAS  PubMed  Google Scholar 

  18. Di Vuolo V, Buonaguro L, Izzo F, Losito S, Botti G, Buonaguro FM, et al. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infectious Agents Cancer. 2011;6:13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Anzola M, Cuevas N, Lopez-Martinez M, Saiz A, Burgos JJ, de Pancorbo MM. Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett. 2003;193(2):199–205.

    Article  CAS  PubMed  Google Scholar 

  20. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999;29(3):697–702.

    Article  CAS  PubMed  Google Scholar 

  21. Leveri M, Gritti C, Rossi L, Zavaglia C, Civardi E, Mondelli MU, et al. Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett. 2004;208(1):75–9.

    Article  CAS  PubMed  Google Scholar 

  22. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412–7.

    Article  CAS  PubMed  Google Scholar 

  23. Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524(2):156–60.

    Article  CAS  PubMed  Google Scholar 

  24. Mah YH, Hsu CS, Liu CH, Liu CJ, Lai MY, Chen PJ, et al. Serum p53 gene polymorphisms and severity of hepatitis B or C-related chronic liver diseases in Taiwan. Hepatol Int. 2011;5(3):814–21.

    Article  PubMed  Google Scholar 

  25. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005;5(1):3–8.

    Article  CAS  PubMed  Google Scholar 

  26. Schlott T, Ahrens K, Ruschenburg I, Reimer S, Hartmann H, Droese M. Different gene expression of MDM2, GAGE-1, -2 and FHIT in hepatocellular carcinoma and focal nodular hyperplasia. Br J Cancer. 1999;80(1-2):73–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994;86(17):1325–30.

    Article  CAS  PubMed  Google Scholar 

  28. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer. 1995;71(5):981–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol. 1995;175(1):31–8.

    Article  CAS  PubMed  Google Scholar 

  30. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119(5):591–602.

    Article  CAS  PubMed  Google Scholar 

  31. Wang X, Zhang X, Qiu B, Tang Y, Sun H, Ji H, et al. MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virus-related hepatocellular carcinoma in a northeast Han Chinese population. Liver Int. 2012;32(7):1172–8.

    Article  CAS  PubMed  Google Scholar 

  32. Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12(16):4867–71.

    Article  CAS  PubMed  Google Scholar 

  33. Akkiz H, Sumbul AT, Bayram S, Bekar A, Akgollu E. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer epidemiology. 2010;34(4):448–52.

    Article  CAS  PubMed  Google Scholar 

  34. Ezzikouri S, El Feydi AE, Afifi R, El Kihal L, Benazzouz M, Hassar M, et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev. 2009;32(5-6):380–5.

    Article  CAS  PubMed  Google Scholar 

  35. Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol. 2009;15(44):5592–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tomoda T, Nouso K, Sakai A, Ouchida M, Kobayashi S, Miyahara K, et al. Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol. 2012;27(4):797–804.

    Article  PubMed  Google Scholar 

  37. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 2006;38(10):1133–41.

    Article  CAS  PubMed  Google Scholar 

  38. Hu S, Zhao L, Yang J, Hu M. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases. Tumour Biol. 2014;35(4):3647–56.

    Article  CAS  PubMed  Google Scholar 

  39. Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun T, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat. 2006;27(1):110–7.

    Article  CAS  PubMed  Google Scholar 

  40. Ezzikouri S, Essaid El Feydi A, Afifi R, Benazzouz M, Hassar M, Pineau P, et al. Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers. 2011;26(4):229–33.

    CAS  PubMed  Google Scholar 

  41. Chen QW, Chen H, Cheng JS, Meng ZQ. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis. Tumour Biol. 2014;35(5):4147–51.

    Article  CAS  PubMed  Google Scholar 

  42. Yang M, Guo Y, Zhang X, Miao X, Tan W, Sun T, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis. 2007;28(9):1996–2001.

    Article  CAS  PubMed  Google Scholar 

  43. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997;420(1):25–7.

    Article  CAS  PubMed  Google Scholar 

  44. Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, et al. Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol. 2002;64(5-6):865–71.

    Article  CAS  PubMed  Google Scholar 

  45. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A. 1999;96(6):3077–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69(7):1237–45.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatobiliary Surgery, The Affiliated Hospital of Guilin Medical College, 15 Le qun Road, Guilin, 541001, China

    Moqin Qiu, Bo Tang & Songqing He

  2. Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, 18 ** zhou Road, Nanning, 530028, China

    Yingchun Liu

  3. Department of Epidemiology and Statistics, School of Public Health, Guilin Medical College, 109 Huan cheng Road, Guilin, 541004, China

    ** Yu

  4. Department of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, 22 Shuang yong Road, Nanning, 530021, China

    **aoyun Zeng & **aoqiang Qiu

Authors
  1. Moqin Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yingchun Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. **angyuan Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Linyuan Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chunhua Bei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. **aoyun Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. **aoqiang Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bo Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Songqing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hong** Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong** Yu.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiu, M., Liu, Y., Yu, X. et al. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma. Tumor Biol. 37, 3863–3870 (2016). https://doi.org/10.1007/s13277-015-4222-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4222-4

Keywords

Search

Navigation